PRCT Stock Recent News

PROCEPT BioRobotics Corporation (PRCT) delivered earnings and revenue surprises of -8.51% and 17.97%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Procept BioRobotics went public in September 2021, raising approximately $164 million in an IPO. The firm is commercializing a water-based ablation device to treat benign prostatic hyperplasia, a common condition in older men.

REDWOOD CITY, Calif., Aug. 22, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present and host a fireside chat at the upcoming 2022 Wells Fargo healthcare conference. Management is scheduled to present on Wednesday, September 7 at 9:10 a.m. Eastern Time. A live webcast of each event, as well as an archived recording, will be available on the “Investors” section of the company's website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after the event.

PROCEPT BioRobotics Corporation (NASDAQ:PRCT ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Matt Bacso - Investor Relations Reza Zadno - Chief Executive Officer Kevin Waters - Chief Financial Officer Conference Call Participants Joshua Jennings - Cowen Craig Bijou - Bank of America Amit Hazan - Goldman Sachs Matthew Mishan - KeyBanc Neil Chatterji - B. Riley Operator Good afternoon, and welcome to PROCEPT BioRobotics Second Quarter Earnings Conference Call.

REDWOOD CITY, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter 2022 after market close on Thursday, August 4, 2022. The company's management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

PROCEPT has developed a system to treat enlarged prostate disease, and is banking on competitive advantage over legacy treatment options. The common disease, more prevalent as populations grow older, provides the company with a large TAM to drive growth.

PROCEPT BioRobotics Corporation (NASDAQ:PRCT ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Matt Bacso - Investor Relations Reza Zadno - Chief Executive Officer Kevin Waters - Chief Financial Officer Conference Call Participants Josh Jennings - Cowen Craig Bijou - Bank of America Amit Hazan - Goldman Sachs Matt Bacso Thanks, operator. Good afternoon and thank you for participating in today's call.

REDWOOD CITY, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the first quarter 2022 after market close on Thursday, May 5, 2022. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.